Valeant Pharmaceuticals Intl Inc.: Value Trap or Opportunity?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to come up as a potential investment option, but is that level of risk right for your portfolio?

| More on:
The Motley Fool

Among the dizzying array of investment opportunities on the market, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to attract significant attention from both buying and selling pundits.

After an epic collapse two years ago, Valeant has been striving to rebuild itself, with investors stuck on either side wondering whether the company is a viable investment opportunity or not.

Here’s a look at both options.

Why is Valeant a buying opportunity?

In the past three-month period, the stock has dropped nearly 10%, but it’s not quite down to 52-week lows. As the stock currently stands, it has a market cap of $4.8 billion, which — when considering some of the assets that continue to garner significant revenue — is quite cheap.

There’s no doubt that investors are factoring Valeant’s massive debt load into that depressed price, and investors burned by the drop a few years ago are left with a bitter feeling towards the stock.

The two factors keeping Valeant down relate to the prior business model the company used and the mountain of debt Valeant continues to be straddled with. From a debt standpoint, Valeant has stated on more than one occasion that the intent of the company is not to eliminate all debt, but rather get it to a more manageable level, which CEO Joseph Papa has said falls between US$15 billion and US$20 billion.

That’s a smaller mountain to climb, but it still represents a challenge for the company, leading to my second point on operations.

One of the main criticisms of Valeant was that the business model the company adhered to was unsustainable. Taking out cheap loans, acquiring drug companies, hiking drug prices, and then repeating those steps provided an avenue for both rapid growth and massive debt.

Valeant has since distanced itself from that model, setting up new distributor agreements and ceasing acquisitions for the moment. The company has also made several deals to sell off non-core assets to raise funds to pay down that mountain of debt, making progress towards debt obligations maturing over the next two years.

Proponents of Valeant see the company as a work in progress that could, in time, become a feasible investment option.

Why you shouldn’t buy Valeant

The other side of the story is less optimistic. Valeant has already amassed a massive amount of debt that rivals some third-world nations. The sheer amount of debt makes a turnaround difficult, but the solution that Valeant has suggested will only snowball the issue.

By selling off non-core assets, Valeant is raising money to pay down the debt, but there are two issues:

First, once sold, that asset no longer contributes to Valeant’s revenue stream, effectively making the selling price a one-time boost at the cost of long-term revenue.

The second point relates to the selling price itself. Rival pharmaceutical companies are more than aware of Valeant’s predicament and will likely leverage that desperation for a sale in price negotiations. What would have been an otherwise quick sale of assets can become a long-winded, drawn-out process that will yield a lower sale prices.

Finally, there are new drugs to consider. Valeant is no longer in an acquisition mode, and while the current crop of products provides a revenue stream for the company, the lack of new advancements and acquisitions could leave the company behind competitors over the long run.

Final thoughts

Investors looking for long-term growth with a massive appetite for risk may want to consider Valeant, but doing so is not for everyone. This is no longer the same company that traded +$200 per share, and it will likely never return to those levels.

In my opinion, there are far better, more stable investments on the market that can provide better growth for your investment.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

clock time
Dividend Stocks

Time to Buy: 1 Canadian Stock Cheaper Than it’s Been in Years

This Canadian stock offers it all: a cheap share price, strong long-term outlook, and brands everyone recognizes.

Read more »

Canadian Dollars bills
Dividend Stocks

Invest $7,000 in This Dividend Stock for $414 in Passive Income

Generate a tax-free quarterly income of $103.73, amounting to $414.92 per year with this top Canadian dividend stock.

Read more »

a-developer-typing-lines-of-ai-code-while-viewing-multiple-computer-monitors
Tech Stocks

Billionaires Are Selling Amazon Stock and Buying This TSX Stock in Bulk

These two tech stocks are both heavily into e-commerce and artificial intelligence, but one simply has more room to grow…

Read more »

shopper chooses vegetables at grocery store
Investing

Loblaw: Buy, Sell, or Hold in 2025?

Loblaw Companies (TSX:L) stock has been a strong performer in 2024. It's still worth checking out around its highs.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Thursday, January 16

The U.S. manufacturing and retail sales numbers are likely to remain on TSX investors’ radar today.

Read more »

Beware of bad investing advice.
Investing

2 No-Brainer Growth Stocks to Buy Right Now for Less Than $500

Both of these top Canadian stocks have impressive track records and years of growth potential, making them two of the…

Read more »

telehealth stocks
Investing

Got $100? 3 Small-Cap Stocks to Buy and Hold Forever

Given their solid underlying businesses and healthy growth prospects, these three small-cap stocks can deliver superior returns in the long…

Read more »

Aircraft Mechanic checking jet engine of the airplane
Investing

CAE Stock: Buy, Sell, or Hold in 2025?

With a record $18B backlog but a retiring CEO and Boeing delays clouding the outlook, is CAE stock's 6% dip…

Read more »